

# Stefania Napolitano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8858647/publications.pdf>

Version: 2024-02-01

53  
papers

1,550  
citations

411340

20  
h-index

371746

37  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2451  
citing authors

| #  | ARTICLE  | IF    | CITATIONS |
|----|--|-------|-----------|
| 1  | Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148. | 1.0   | 10        |
| 2  | Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.. <i>Journal of Clinical Oncology</i> , 2022, 40, 145-145.  | 0.8   | 0         |
| 3  | PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples. <i>Diagnostics</i> , 2022, 12, 646.   | 1.3   | 4         |
| 4  | Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.                   | 3.5   | 7         |
| 5  | Immunotherapy for head and neck cancer: Present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103679.  | 2.0   | 45        |
| 6  | Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 708.   | 1.0   | 4         |
| 7  | Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.   | 2.3   | 24        |
| 8  | Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210968.                                | 1.4   | 8         |
| 9  | Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.   | 157.7 | 167       |
| 10 | Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. <i>Cancers</i> , 2022, 14, 3053.   | 1.7   | 7         |
| 11 | Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 15.  | 3.5   | 13        |
| 12 | Dual inhibition of TGFÎ² and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.  | 1.2   | 7         |
| 13 | Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. <i>Journal of Personalized Medicine</i> , 2021, 11, 206.  | 1.1   | 2         |
| 14 | NMR Profiling of Ononis diffusa Identifies Cytotoxic Compounds against Cetuximab-Resistant Colon Cancer Cell Lines. <i>Molecules</i> , 2021, 26, 3266.   | 1.7   | 2         |
| 15 | Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021165S.  | 0.5   | 0         |
| 16 | Multiple acquired mutations captured by liquid biopsy in the EGFR addicted metastatic colorectal cancer.. <i>Clinical Colorectal Cancer</i> , 2021, , .  | 1.0   | 1         |
| 17 | Hypothalamicâ€Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. <i>Cancers</i> , 2021, 13, 4036.  | 1.7   | 3         |
| 18 | Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.   | 3.4   | 80        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.                     | 1.0 | 10        |
| 20 | Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.   | 1.7 | 6         |
| 21 | Baseline IFN- $\gamma$ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.  | 1.6 | 20        |
| 22 | Towards the era of precision medicine in metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000685.  | 2.0 | 0         |
| 23 | Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.   | 1.4 | 31        |
| 24 | Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli". <i>ESMO Open</i> , 2020, 5, e000675.  | 2.0 | 11        |
| 25 | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.  | 3.4 | 34        |
| 26 | Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.   | 3.2 | 76        |
| 27 | Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.  | 1.7 | 36        |
| 28 | Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41. | 3.5 | 57        |
| 29 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.   | 3.5 | 17        |
| 30 | EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.                                    | 1.9 | 58        |
| 31 | How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.  | 2.0 | 49        |
| 32 | Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. <i>ESMO Open</i> , 2019, 4, e000551.  | 2.0 | 15        |
| 33 | A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. <i>Medicine (United States)</i> , 2019, 98, e15759.   | 0.4 | 6         |
| 34 | Novel <i>In Vitro</i> Cancer Models for Optimizing Anti-EGFR Therapies. <i>Clinical Cancer Research</i> , 2018, 24, 727-729.   | 3.2 | 2         |
| 35 | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.  | 2.0 | 27        |
| 36 | Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. <i>ESMO Open</i> , 2017, 2, e000229.                                   | 2.0 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.  | 1.4 | 91        |
| 38 | Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 82773-82783.      | 0.8 | 8         |
| 39 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.   | 0.8 | 15        |
| 40 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.   | 0.8 | 27        |
| 41 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016, 1, e000088.   | 2.0 | 85        |
| 42 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.   | 1.4 | 94        |
| 43 | Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.                            | 3.2 | 21        |
| 44 | Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015, 21, 2975-2983.                            | 3.2 | 63        |
| 45 | Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 217-224.   | 1.0 | 1         |
| 46 | Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3634-TPS3634.  | 0.8 | 2         |
| 47 | Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS789-TPS789.  | 0.8 | 2         |
| 48 | AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015, 6, 23281-23296.   | 0.8 | 55        |
| 49 | Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 279-287.   | 1.0 | 0         |
| 50 | Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. <i>Clinical Cancer Research</i> , 2014, 20, 3775-3786.        | 3.2 | 89        |
| 51 | Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 299-308.   | 0.8 | 0         |
| 52 | Increased TGF- $\beta$ as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6751-6765. | 3.2 | 130       |
| 53 | CAVE-2 (Cetuximab-Avelumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. <i>Frontiers in Oncology</i> , 0, 12, .      | 1.3 | 14        |